drugset / Trial / NCT01338896

Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations

NCT01338896

Phase 1 Completed 56 enrolled UCB Pharma
RandomizedCrossoverQuadruple-blindTreatment

Summary

The primary objective of the study is to compare the adhesiveness of two different patch formulations of rotigotine using patch size 40 cm2, under the assumption that both patch formulations show similar adhesiveness properties.

Timeline

Start
2011-04
Primary completion
2011-05
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 8 mg Other

Indications